Abstract

OBJECTIVES

The aim of this study was to examine the incidence and predictors of stroke after minimally invasive mitral valve surgery (mini-MVS) and to assess the role of preoperative CT scan on surgical management and neurological outcomes in the large cohort of Mini-Mitral International Registry.

METHODS

Clinical, operative and in-hospital outcomes in patients undergoing mini-MVS between 2015 and 2021 were collected. Univariable and multivariable analyses were used to identify predictors of stroke. Finally, the impact of preoperative CT scan on surgical management and neurological outcomes was assessed.

RESULTS

Data from 7343 patients were collected. The incidence of stroke was 1.3% (n = 95/7343). Stroke was associated with higher in-hospital mortality (11.6% vs 1.5%, P < 0.001) and longer intubation time, ICU and hospital stay (median 26 vs 7 h, 120 vs 24 h and 14 vs 8 days, respectively). On multivariable analysis, age (odds ratio 1.039, 95% confidence interval 1.019–1.060, P < 0.001) and mitral valve replacement (odds ratio 2.167, 95% confidence interval 1.401–3.354, P < 0.001) emerged as independent predictors of stroke. Preoperative CT scan was made in 31.1% of cases. These patients had a higher risk profile and EuroSCORE II (median 1.58 vs 1.1, P < 0.001). CT scan influenced the choice of cannulation site, being ascending aorta (18.5% vs 0.5%, P < 0.001) more frequent in the CT group and femoral artery more frequent in the no CT group (97.8% vs 79.7%, P < 0.001). No difference was found in the incidence of postoperative stroke (CT group 1.5, no CT group 1.4%, P = 0.7).

CONCLUSIONS

Mini-MVS is associated with a low incidence of stroke, but when it occurs it has an ominous impact on mortality. Preoperative CT scan affected surgical cannulation strategy but did not led to improved neurological outcomes.

INTRODUCTION

Neurological injury is a devastating complication after cardiovascular surgery. The incidence of stroke following a cardiac operation ranges from 1.6% to 6% [1–4], and when it occurs it has serious consequences, influencing postoperative mortality rate and patients’ quality of life [5]. In the past, an increasing risk of stroke following minimally invasive mitral valve surgery (mini-MVS) compared with standard sternotomy has been reported [6]. However, despite initial concerns about aortic injuries and particularly stroke, recent data from single-centre retrospective studies showed a stroke rate of 0.8–2% [7–9]. Furthermore, a recent meta-analysis showed that, despite longer operative times, mini-MVS, in comparison with sternotomy approach, reduces ICU and hospital stay and does not increase the risk of stroke [10].

In the present study, we aimed to examine the incidence and predictors of stroke in patients undergoing mini-MVS in the largest cohort of patients whose data were collected in the Mini-Mitral International Registry (MMIR) and to assess the role of preoperative CT scan on surgical management and neurological outcomes.

PATIENTS AND METHODS

Ethical statement

The study protocol was approved by the local institutional review board (no. 2020189, 30 July 2020). Consent of patients was waived for the retrospective phase, whereas was obtained for the patients enrolled prospectively.

Mini-Mitral International Registry and study population

The MMIR is an independent registry involving 17 international heart valve centres. Details of the registry have been published previously [11]. The Centres combined all consecutive patients who received minimally invasive mitral valve operations with or without associated procedures between 2015 and 2021. Perioperative characteristics and in-hospital outcomes of patients were collected according to the current European Society of Cardiology or ACC/AHA/HRS Guidelines [12], EuroSCORE II model [13] and Mitral Valve Academy Research Consortium end point definitions [14].

Study end points and outcome definitions

The primary end point was to evaluate the incidence and predictors of stroke in patients undergoing mini-MVS. Stroke was defined, according to the Mitral Valve Academy Research Consortium definition, as duration of a focal or global neurological deficit ≥24 or <24 h if available neuroimaging documents a new intracranial or subarachnoid haemorrhage or central nervous system infarction or the neurological deficit results in death.

The secondary end point was to assess the role of preoperative CT scan on surgical management and neurological outcomes.

Bleeding was defined as any postoperative haemorrhage requiring surgical revision.

Statistical analysis

Continuous variables were expressed as mean (standard deviation) and categorical variables as percentages. Where continuous variables did not follow a normal distribution, the median and interquartile range (IQR) were reported. In all cases, missing data were not defaulted to negative, and denominators reflect only cases reported. The association between covariates and stroke was tested using univariable and multivariable binary logistic regressions. The multivariable model included 18 pre- and intraoperative clinically relevant covariates: sex, age, diabetes, atrial fibrillation, endocarditis, peripheral arteriopathy, previous neurological injury, cerebrovascular arteriopathy, dialysis, previous cardiac surgery, reduced LVEF, urgent/emergent status, arterial cannulation site, myocardial protection, type of mitral valve surgery (MVS), type of valve prosthesis, concomitant tricuspid and atrial fibrillation surgery. The backward stepwise method was used to build the final model (adjusted R2: 0.22).

Propensity score matching was used for subgroup analysis (CT scan versus no CT scan). The matched groups were compared using standard univariate statistical tests of association. Details on PS-matching and comparisons were reported in the Supplementary Material. The level of significance, α, was set at 5%. Statistical analysis was performed using Statistical Package for Social Sciences version 28.0 (IBM SPSS Inc., Chicago, IL, USA).

RESULTS

Demographic and baseline data

Perioperative characteristics and in-hospital outcomes of 7513 patients were collected. Patients with missing data on the key study variable—stroke (n = 28)—and those who received concomitant aortic valve or root/ascending aorta replacement (n = 142) were excluded. Subgroup analysis on preoperative CT scan included only patients with available CT scan data.

The analysis then included a total of 7343 patients. Baseline and preoperative characteristics of the populations are shown in Table 1. The median age was 65 years (55–73) with male predominance (n = 4239, 57.8%) and a median EuroSCORE II of 1.31% (0.81–2.73). A history of neurologic injury was present in 535 patients (7.4%) and an active endocarditis in 272 cases (3.7%), while 560 patients (7.7%) had prior cardiac surgery.

Table 1:

Patients’ characteristics (n = 7343)

N%
Male423957.8
Age, median (IQR)65 (55–73)
NYHA class III–IV333747.7
Hypertension389658.1
Diabetes6538.9
Smoking88313.2
Obesity102314.4
AF252037.2
PM2343.2
Mitral valve regurgitation (moderate–severe)683693.1
Mitral valve stenosis (moderate–severe)5117.6
Active endocarditis2723.7
Cerebrovascular arteriopathy1341.9
Peripheral arteriopathy1982.7
History of neurological injury5357.4
Pulmonary hypertension280440
Dialysis831.1
CAD100114
Chronic lung disease6629
Previous cardiac surgery5607.7
 Mitral valve surgery3224.4
 Aortic valve surgery1642.2
 CABG1492.1
 Root/ascending aorta surgery510.7
 Other surgery891.2
Reduced LVEF (≤50%)130518
Preoperative CT scan175031.1
Critical preoperative state1902.7
Urgent/emergent status4816.5
EuroSCORE II, median (IQR)1.31 (0.81–2.73)
N%
Male423957.8
Age, median (IQR)65 (55–73)
NYHA class III–IV333747.7
Hypertension389658.1
Diabetes6538.9
Smoking88313.2
Obesity102314.4
AF252037.2
PM2343.2
Mitral valve regurgitation (moderate–severe)683693.1
Mitral valve stenosis (moderate–severe)5117.6
Active endocarditis2723.7
Cerebrovascular arteriopathy1341.9
Peripheral arteriopathy1982.7
History of neurological injury5357.4
Pulmonary hypertension280440
Dialysis831.1
CAD100114
Chronic lung disease6629
Previous cardiac surgery5607.7
 Mitral valve surgery3224.4
 Aortic valve surgery1642.2
 CABG1492.1
 Root/ascending aorta surgery510.7
 Other surgery891.2
Reduced LVEF (≤50%)130518
Preoperative CT scan175031.1
Critical preoperative state1902.7
Urgent/emergent status4816.5
EuroSCORE II, median (IQR)1.31 (0.81–2.73)

CABG: Coronary Artery Bypass Grafting; IQR: interquartile range; NYHA: New York Heart Association; AF: Atrial Fibrillation; PM: Pace Maker; CAD: coronary artery disease.

Table 1:

Patients’ characteristics (n = 7343)

N%
Male423957.8
Age, median (IQR)65 (55–73)
NYHA class III–IV333747.7
Hypertension389658.1
Diabetes6538.9
Smoking88313.2
Obesity102314.4
AF252037.2
PM2343.2
Mitral valve regurgitation (moderate–severe)683693.1
Mitral valve stenosis (moderate–severe)5117.6
Active endocarditis2723.7
Cerebrovascular arteriopathy1341.9
Peripheral arteriopathy1982.7
History of neurological injury5357.4
Pulmonary hypertension280440
Dialysis831.1
CAD100114
Chronic lung disease6629
Previous cardiac surgery5607.7
 Mitral valve surgery3224.4
 Aortic valve surgery1642.2
 CABG1492.1
 Root/ascending aorta surgery510.7
 Other surgery891.2
Reduced LVEF (≤50%)130518
Preoperative CT scan175031.1
Critical preoperative state1902.7
Urgent/emergent status4816.5
EuroSCORE II, median (IQR)1.31 (0.81–2.73)
N%
Male423957.8
Age, median (IQR)65 (55–73)
NYHA class III–IV333747.7
Hypertension389658.1
Diabetes6538.9
Smoking88313.2
Obesity102314.4
AF252037.2
PM2343.2
Mitral valve regurgitation (moderate–severe)683693.1
Mitral valve stenosis (moderate–severe)5117.6
Active endocarditis2723.7
Cerebrovascular arteriopathy1341.9
Peripheral arteriopathy1982.7
History of neurological injury5357.4
Pulmonary hypertension280440
Dialysis831.1
CAD100114
Chronic lung disease6629
Previous cardiac surgery5607.7
 Mitral valve surgery3224.4
 Aortic valve surgery1642.2
 CABG1492.1
 Root/ascending aorta surgery510.7
 Other surgery891.2
Reduced LVEF (≤50%)130518
Preoperative CT scan175031.1
Critical preoperative state1902.7
Urgent/emergent status4816.5
EuroSCORE II, median (IQR)1.31 (0.81–2.73)

CABG: Coronary Artery Bypass Grafting; IQR: interquartile range; NYHA: New York Heart Association; AF: Atrial Fibrillation; PM: Pace Maker; CAD: coronary artery disease.

Perioperative data

Intraoperative variables are resumed in Table 2. The surgical approaches included: direct vision (28.5%), video-assisted (41%), fully endoscopic (27.4%) and robotic (0.7%). Conversion to full sternotomy occurred in 135 cases (1.9%). Femoral artery was the most used cannulation site for cardiopulmonary bypass (CPB) inflow (n = 6645, 92.8%). The main surgical procedure involved mitral valve repair in 5502 patients (74.9%) and mitral valve replacement in 1840 (25.1). In 1240 cases (16.9%), a concomitant tricuspid valve surgery was needed. The median CPB and cross-clamp time were 135 (107–172) and 84 min (64–109), respectively. Repeated cross-clamping was observed in 164 patients (2.3%).

Table 2:

Operative data

N%
Surgical approach
 Direct vision208928.5
 Video assisted301041
 Totally endoscopic218427.4
 Robotic540.7
Surgical access
 Anterolateral542974
 Transaxillary91812.5
 Periareolar6959.5
 Ministernotomy2984.1
Conversion to full sternotomy1351.9
Arterial cannulation site
 Femoral artery664592.8
 Axillary artery1371.9
 Ascending aorta3284.6
 Other490.7
Myocardial protection
 Cardioplegia712397.6
 Ventricular fibrillation1492
 Beating heart260.4
Aortic cross-clamping type
 External clamp604084.3
 Endoclamp112215.7
Type of surgery
Mitral valve repair550274.9
Mitral valve replacement184025.1
Type of valve prosthesis
Biological134118.4
Mechanical4606.3
 Concomitant tricuspid surgery124016.9
 Concomitant AF surgery130117.7
LAAA closure99414.1
Repeated cross-clamping1642.3
CPB time, median (IQR)135 (107–172)
Cross-clamp time, median (IQR)84 (64–109)
N%
Surgical approach
 Direct vision208928.5
 Video assisted301041
 Totally endoscopic218427.4
 Robotic540.7
Surgical access
 Anterolateral542974
 Transaxillary91812.5
 Periareolar6959.5
 Ministernotomy2984.1
Conversion to full sternotomy1351.9
Arterial cannulation site
 Femoral artery664592.8
 Axillary artery1371.9
 Ascending aorta3284.6
 Other490.7
Myocardial protection
 Cardioplegia712397.6
 Ventricular fibrillation1492
 Beating heart260.4
Aortic cross-clamping type
 External clamp604084.3
 Endoclamp112215.7
Type of surgery
Mitral valve repair550274.9
Mitral valve replacement184025.1
Type of valve prosthesis
Biological134118.4
Mechanical4606.3
 Concomitant tricuspid surgery124016.9
 Concomitant AF surgery130117.7
LAAA closure99414.1
Repeated cross-clamping1642.3
CPB time, median (IQR)135 (107–172)
Cross-clamp time, median (IQR)84 (64–109)

AF: atrial fibrillation; CPB: cardiopulmonary bypass; IQR: interquartile range; LAA: left atrial appendage.

Table 2:

Operative data

N%
Surgical approach
 Direct vision208928.5
 Video assisted301041
 Totally endoscopic218427.4
 Robotic540.7
Surgical access
 Anterolateral542974
 Transaxillary91812.5
 Periareolar6959.5
 Ministernotomy2984.1
Conversion to full sternotomy1351.9
Arterial cannulation site
 Femoral artery664592.8
 Axillary artery1371.9
 Ascending aorta3284.6
 Other490.7
Myocardial protection
 Cardioplegia712397.6
 Ventricular fibrillation1492
 Beating heart260.4
Aortic cross-clamping type
 External clamp604084.3
 Endoclamp112215.7
Type of surgery
Mitral valve repair550274.9
Mitral valve replacement184025.1
Type of valve prosthesis
Biological134118.4
Mechanical4606.3
 Concomitant tricuspid surgery124016.9
 Concomitant AF surgery130117.7
LAAA closure99414.1
Repeated cross-clamping1642.3
CPB time, median (IQR)135 (107–172)
Cross-clamp time, median (IQR)84 (64–109)
N%
Surgical approach
 Direct vision208928.5
 Video assisted301041
 Totally endoscopic218427.4
 Robotic540.7
Surgical access
 Anterolateral542974
 Transaxillary91812.5
 Periareolar6959.5
 Ministernotomy2984.1
Conversion to full sternotomy1351.9
Arterial cannulation site
 Femoral artery664592.8
 Axillary artery1371.9
 Ascending aorta3284.6
 Other490.7
Myocardial protection
 Cardioplegia712397.6
 Ventricular fibrillation1492
 Beating heart260.4
Aortic cross-clamping type
 External clamp604084.3
 Endoclamp112215.7
Type of surgery
Mitral valve repair550274.9
Mitral valve replacement184025.1
Type of valve prosthesis
Biological134118.4
Mechanical4606.3
 Concomitant tricuspid surgery124016.9
 Concomitant AF surgery130117.7
LAAA closure99414.1
Repeated cross-clamping1642.3
CPB time, median (IQR)135 (107–172)
Cross-clamp time, median (IQR)84 (64–109)

AF: atrial fibrillation; CPB: cardiopulmonary bypass; IQR: interquartile range; LAA: left atrial appendage.

In-hospital outcomes

In-hospital results are shown in Table 3. The overall mortality was 1.7%. The main postoperative complications included stroke (1.3%), bleeding (6%), low cardiac output (3.8%) and dialysis (1.8%). Median ventilation, ICU times and hospital stay were 8 h (IQR 5–13), 24 h (IQR 20–48) and 8 days (IQR 6–11), respectively.

Table 3:

In-hospital outcomes

N%
In-hospital mortality1221.7
Delirium4026.2
Intubation time (h), median (IQR)8 (5–13)
Bleeding requiring revision4206
New-onset AF106315.8
Definitive PM implantation4536.2
Myocardial infarction590.8
Low cardiac output syndrome2733.8
Dialysis1151.8
Vascular complications
Major vasc. complications861.3
Minor vasc. complications420.6
Thoracic wound complications1041.4
Redo for early valve repair failure590.9
ICU stay (h), median (IQR)24 (20–48)
Hospital stay (days), median (IQR)8 (6–11)
N%
In-hospital mortality1221.7
Delirium4026.2
Intubation time (h), median (IQR)8 (5–13)
Bleeding requiring revision4206
New-onset AF106315.8
Definitive PM implantation4536.2
Myocardial infarction590.8
Low cardiac output syndrome2733.8
Dialysis1151.8
Vascular complications
Major vasc. complications861.3
Minor vasc. complications420.6
Thoracic wound complications1041.4
Redo for early valve repair failure590.9
ICU stay (h), median (IQR)24 (20–48)
Hospital stay (days), median (IQR)8 (6–11)

AF: atrial fibrillation; IQR: interquartile range; PM: Pace Maker.

Table 3:

In-hospital outcomes

N%
In-hospital mortality1221.7
Delirium4026.2
Intubation time (h), median (IQR)8 (5–13)
Bleeding requiring revision4206
New-onset AF106315.8
Definitive PM implantation4536.2
Myocardial infarction590.8
Low cardiac output syndrome2733.8
Dialysis1151.8
Vascular complications
Major vasc. complications861.3
Minor vasc. complications420.6
Thoracic wound complications1041.4
Redo for early valve repair failure590.9
ICU stay (h), median (IQR)24 (20–48)
Hospital stay (days), median (IQR)8 (6–11)
N%
In-hospital mortality1221.7
Delirium4026.2
Intubation time (h), median (IQR)8 (5–13)
Bleeding requiring revision4206
New-onset AF106315.8
Definitive PM implantation4536.2
Myocardial infarction590.8
Low cardiac output syndrome2733.8
Dialysis1151.8
Vascular complications
Major vasc. complications861.3
Minor vasc. complications420.6
Thoracic wound complications1041.4
Redo for early valve repair failure590.9
ICU stay (h), median (IQR)24 (20–48)
Hospital stay (days), median (IQR)8 (6–11)

AF: atrial fibrillation; IQR: interquartile range; PM: Pace Maker.

Neurological outcomes

The overall incidence of perioperative stroke was 1.3% (n = 95). In-hospital mortality in patients who had stroke was 11.6% (n = 11). On multivariable analysis age [odds ratio (OR) 1.039, 95% confidence interval (CI) 1.019–1.060, P < 0.001], urgent/emergent status (OR 2.095, 95% CI 1.137–3.857, P = 0.02) and mitral valve replacement (OR 2.167, 95% CI 1.401–3.354, P < 0.001) emerged as independent predictors of stroke (Table 4).

Table 4:

Multivariable analysis for stroke

VariableP-valueOR/HR95% Cl
Age<0.0011.0391.019–1.060
Urgent/emergent status0.022.0951.137–3.857
Reduced LVEF
Mitral valve replacement<0.0012.1671.401–3.354
VariableP-valueOR/HR95% Cl
Age<0.0011.0391.019–1.060
Urgent/emergent status0.022.0951.137–3.857
Reduced LVEF
Mitral valve replacement<0.0012.1671.401–3.354

CI: confidence interval; OR: odds ratio.

Table 4:

Multivariable analysis for stroke

VariableP-valueOR/HR95% Cl
Age<0.0011.0391.019–1.060
Urgent/emergent status0.022.0951.137–3.857
Reduced LVEF
Mitral valve replacement<0.0012.1671.401–3.354
VariableP-valueOR/HR95% Cl
Age<0.0011.0391.019–1.060
Urgent/emergent status0.022.0951.137–3.857
Reduced LVEF
Mitral valve replacement<0.0012.1671.401–3.354

CI: confidence interval; OR: odds ratio.

CT scan analysis

Patients with available CT scan data were 5626 (76.6%). A preoperative CT scan was made in the 31.1% of patients. These patients had a higher risk profile [median EuroSCORE II 1.58 (IQR 0.9–3.1) vs 1.1 (0.73–2.01), P < 0.001] compared with those who did not undergo CT scan (Table 5). When a preoperative CT scan was made, it influenced the choice of arterial cannulation site, being ascending aorta (18% vs 0.4%, P < 0.001) more frequent in the CT group and femoral artery more frequent in the no CT group (97.9% vs 80.2%, P < 0.001) (Table 6). The incidence of mortality (1.7% and 1.4%, P = NS) and stroke (1.5 vs 1.4%, P = NS) was not different between the CT and no CT groups (Table 7). Even after the propensity score analysis, no differences were found between the CT and no CT groups in terms of in-hospital mortality (1.3 vs 1.5%, P = NS) and stroke (1.2 vs 0.7%, P = NS).

Table 5:

Patients’ characteristics (N = 5626)

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)Standardized mean differenceCT group (n = 1185), N (%)No CT group (n = 1185), N(%)Standardized mean difference
Male977 (55.9)2328 (60.2)−15.6504 (42.5)479 (40.4)6.4
Age, median (IQR)65 (54–73)64 (55–72)8.464 (53–73)64 (52–72)3.6
NYHA class III–IV820 (47.3)1618 (42.5)13.1523 (44.1)473 (39.9)8.8
Hypertension965 (58.5)2243 (57.9)2.2687 (58)667 (56.3)5.3
Diabetes201 (11.5)265 (6.8)14.392 (7.8)100 (8.4)−4.2
Smoking252 (15.4)422 (10.9)16.8143 (12.1)169 (14.3)−8.1
Obesity217 (13.2)570 (15)−8.9154 (13)136 (11.5)4.7
AF707 (40.4)1420 (36.7)14.7441 (37.2)402 (33.9)9.7
PM81 (4.6)80 (2.1)11.833 (2.8)28 (2.4)3.1
Mitral valve regurgitation (moderate–severe)1597 (91.3)3631 (93.8)−9.81118 (94.3)1101 (92.9)5.1
Mitral valve stenosis (moderate–severe)216 (12.3)195 (5)23.686 (7.3)72 (6.1)3.6
Active endocarditis79 (4.5)124 (3.2)7.851 (4.3)45 (3.8)2.5
Cerebrovascular disease50 (2.9)61 (1.6)6.422 (1.9)17 (1.4)2.6
Peripheral arteriopathy38 (2.2)49 (1.3)7.721 (1.8)13 (1.1)1.8
History of neurological injury193 (11.8)218 (5.6)18.484 (7.1)95 (8)−2.4
Pulmonary hypertension564 (32.3)1490 (38.7)−14.2406 (34.3)417 (35.2)−2.6
Dialysis27 (1.5)32 (0.8)9.814 (1.2)11 (0.9)2.1
CAD237 (14.4)485 (12.5)7.7141 (11.9)114 (9.6)5.3
Chronic lung disease199 (11.4)287 (7.4)13.194 (7.9)90 (7.6)0.9
Previous cardiac surgery106 (6.1)158 (4.1)7.858 (4.9)44 (3.7)3.6
 Mitral valve surgery42 (2.4)90 (2.3)2.323 (1.9)24 (2)−0.3
 Aortic valve surgery42 (2.4)38 (1)4.718 (1.5)9 (0.8)1.1
 CABG32 (2)44 (1.1)3.319 (1.6)10 (0.8)2.8
 Root/ascending aorta surgery18 (1)15 (0.4)2.410 (0.8)3 (0.3)1.2
 Other surgery22 (1.3)32 (0.8)2.115 (1.3)13 (1.1)0.9
Reduced LVEF (≤50%)345 (20)649 (17)11.3208 (17.6)174 (14.7)6.3
Critical preoperative state54 (3.1)94 (2.4)6.530 (2.5)30 (2.5)
Urgent/emergent status124 (7.1)234 (6)5.275 (6.3)75 (6.3)
EuroSCORE II, median (IQR)1.58 (0.9–3.1)1.1 (0.73–2.01)14.91.41 (0.83–2.94)1.29 (0.91–2.13)9.4
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)Standardized mean differenceCT group (n = 1185), N (%)No CT group (n = 1185), N(%)Standardized mean difference
Male977 (55.9)2328 (60.2)−15.6504 (42.5)479 (40.4)6.4
Age, median (IQR)65 (54–73)64 (55–72)8.464 (53–73)64 (52–72)3.6
NYHA class III–IV820 (47.3)1618 (42.5)13.1523 (44.1)473 (39.9)8.8
Hypertension965 (58.5)2243 (57.9)2.2687 (58)667 (56.3)5.3
Diabetes201 (11.5)265 (6.8)14.392 (7.8)100 (8.4)−4.2
Smoking252 (15.4)422 (10.9)16.8143 (12.1)169 (14.3)−8.1
Obesity217 (13.2)570 (15)−8.9154 (13)136 (11.5)4.7
AF707 (40.4)1420 (36.7)14.7441 (37.2)402 (33.9)9.7
PM81 (4.6)80 (2.1)11.833 (2.8)28 (2.4)3.1
Mitral valve regurgitation (moderate–severe)1597 (91.3)3631 (93.8)−9.81118 (94.3)1101 (92.9)5.1
Mitral valve stenosis (moderate–severe)216 (12.3)195 (5)23.686 (7.3)72 (6.1)3.6
Active endocarditis79 (4.5)124 (3.2)7.851 (4.3)45 (3.8)2.5
Cerebrovascular disease50 (2.9)61 (1.6)6.422 (1.9)17 (1.4)2.6
Peripheral arteriopathy38 (2.2)49 (1.3)7.721 (1.8)13 (1.1)1.8
History of neurological injury193 (11.8)218 (5.6)18.484 (7.1)95 (8)−2.4
Pulmonary hypertension564 (32.3)1490 (38.7)−14.2406 (34.3)417 (35.2)−2.6
Dialysis27 (1.5)32 (0.8)9.814 (1.2)11 (0.9)2.1
CAD237 (14.4)485 (12.5)7.7141 (11.9)114 (9.6)5.3
Chronic lung disease199 (11.4)287 (7.4)13.194 (7.9)90 (7.6)0.9
Previous cardiac surgery106 (6.1)158 (4.1)7.858 (4.9)44 (3.7)3.6
 Mitral valve surgery42 (2.4)90 (2.3)2.323 (1.9)24 (2)−0.3
 Aortic valve surgery42 (2.4)38 (1)4.718 (1.5)9 (0.8)1.1
 CABG32 (2)44 (1.1)3.319 (1.6)10 (0.8)2.8
 Root/ascending aorta surgery18 (1)15 (0.4)2.410 (0.8)3 (0.3)1.2
 Other surgery22 (1.3)32 (0.8)2.115 (1.3)13 (1.1)0.9
Reduced LVEF (≤50%)345 (20)649 (17)11.3208 (17.6)174 (14.7)6.3
Critical preoperative state54 (3.1)94 (2.4)6.530 (2.5)30 (2.5)
Urgent/emergent status124 (7.1)234 (6)5.275 (6.3)75 (6.3)
EuroSCORE II, median (IQR)1.58 (0.9–3.1)1.1 (0.73–2.01)14.91.41 (0.83–2.94)1.29 (0.91–2.13)9.4

AF: atrial fibrillation; CABG: coronary artery bypass grafting; IQR: interquartile range; NYHA: New York Heart Association.

Table 5:

Patients’ characteristics (N = 5626)

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)Standardized mean differenceCT group (n = 1185), N (%)No CT group (n = 1185), N(%)Standardized mean difference
Male977 (55.9)2328 (60.2)−15.6504 (42.5)479 (40.4)6.4
Age, median (IQR)65 (54–73)64 (55–72)8.464 (53–73)64 (52–72)3.6
NYHA class III–IV820 (47.3)1618 (42.5)13.1523 (44.1)473 (39.9)8.8
Hypertension965 (58.5)2243 (57.9)2.2687 (58)667 (56.3)5.3
Diabetes201 (11.5)265 (6.8)14.392 (7.8)100 (8.4)−4.2
Smoking252 (15.4)422 (10.9)16.8143 (12.1)169 (14.3)−8.1
Obesity217 (13.2)570 (15)−8.9154 (13)136 (11.5)4.7
AF707 (40.4)1420 (36.7)14.7441 (37.2)402 (33.9)9.7
PM81 (4.6)80 (2.1)11.833 (2.8)28 (2.4)3.1
Mitral valve regurgitation (moderate–severe)1597 (91.3)3631 (93.8)−9.81118 (94.3)1101 (92.9)5.1
Mitral valve stenosis (moderate–severe)216 (12.3)195 (5)23.686 (7.3)72 (6.1)3.6
Active endocarditis79 (4.5)124 (3.2)7.851 (4.3)45 (3.8)2.5
Cerebrovascular disease50 (2.9)61 (1.6)6.422 (1.9)17 (1.4)2.6
Peripheral arteriopathy38 (2.2)49 (1.3)7.721 (1.8)13 (1.1)1.8
History of neurological injury193 (11.8)218 (5.6)18.484 (7.1)95 (8)−2.4
Pulmonary hypertension564 (32.3)1490 (38.7)−14.2406 (34.3)417 (35.2)−2.6
Dialysis27 (1.5)32 (0.8)9.814 (1.2)11 (0.9)2.1
CAD237 (14.4)485 (12.5)7.7141 (11.9)114 (9.6)5.3
Chronic lung disease199 (11.4)287 (7.4)13.194 (7.9)90 (7.6)0.9
Previous cardiac surgery106 (6.1)158 (4.1)7.858 (4.9)44 (3.7)3.6
 Mitral valve surgery42 (2.4)90 (2.3)2.323 (1.9)24 (2)−0.3
 Aortic valve surgery42 (2.4)38 (1)4.718 (1.5)9 (0.8)1.1
 CABG32 (2)44 (1.1)3.319 (1.6)10 (0.8)2.8
 Root/ascending aorta surgery18 (1)15 (0.4)2.410 (0.8)3 (0.3)1.2
 Other surgery22 (1.3)32 (0.8)2.115 (1.3)13 (1.1)0.9
Reduced LVEF (≤50%)345 (20)649 (17)11.3208 (17.6)174 (14.7)6.3
Critical preoperative state54 (3.1)94 (2.4)6.530 (2.5)30 (2.5)
Urgent/emergent status124 (7.1)234 (6)5.275 (6.3)75 (6.3)
EuroSCORE II, median (IQR)1.58 (0.9–3.1)1.1 (0.73–2.01)14.91.41 (0.83–2.94)1.29 (0.91–2.13)9.4
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)Standardized mean differenceCT group (n = 1185), N (%)No CT group (n = 1185), N(%)Standardized mean difference
Male977 (55.9)2328 (60.2)−15.6504 (42.5)479 (40.4)6.4
Age, median (IQR)65 (54–73)64 (55–72)8.464 (53–73)64 (52–72)3.6
NYHA class III–IV820 (47.3)1618 (42.5)13.1523 (44.1)473 (39.9)8.8
Hypertension965 (58.5)2243 (57.9)2.2687 (58)667 (56.3)5.3
Diabetes201 (11.5)265 (6.8)14.392 (7.8)100 (8.4)−4.2
Smoking252 (15.4)422 (10.9)16.8143 (12.1)169 (14.3)−8.1
Obesity217 (13.2)570 (15)−8.9154 (13)136 (11.5)4.7
AF707 (40.4)1420 (36.7)14.7441 (37.2)402 (33.9)9.7
PM81 (4.6)80 (2.1)11.833 (2.8)28 (2.4)3.1
Mitral valve regurgitation (moderate–severe)1597 (91.3)3631 (93.8)−9.81118 (94.3)1101 (92.9)5.1
Mitral valve stenosis (moderate–severe)216 (12.3)195 (5)23.686 (7.3)72 (6.1)3.6
Active endocarditis79 (4.5)124 (3.2)7.851 (4.3)45 (3.8)2.5
Cerebrovascular disease50 (2.9)61 (1.6)6.422 (1.9)17 (1.4)2.6
Peripheral arteriopathy38 (2.2)49 (1.3)7.721 (1.8)13 (1.1)1.8
History of neurological injury193 (11.8)218 (5.6)18.484 (7.1)95 (8)−2.4
Pulmonary hypertension564 (32.3)1490 (38.7)−14.2406 (34.3)417 (35.2)−2.6
Dialysis27 (1.5)32 (0.8)9.814 (1.2)11 (0.9)2.1
CAD237 (14.4)485 (12.5)7.7141 (11.9)114 (9.6)5.3
Chronic lung disease199 (11.4)287 (7.4)13.194 (7.9)90 (7.6)0.9
Previous cardiac surgery106 (6.1)158 (4.1)7.858 (4.9)44 (3.7)3.6
 Mitral valve surgery42 (2.4)90 (2.3)2.323 (1.9)24 (2)−0.3
 Aortic valve surgery42 (2.4)38 (1)4.718 (1.5)9 (0.8)1.1
 CABG32 (2)44 (1.1)3.319 (1.6)10 (0.8)2.8
 Root/ascending aorta surgery18 (1)15 (0.4)2.410 (0.8)3 (0.3)1.2
 Other surgery22 (1.3)32 (0.8)2.115 (1.3)13 (1.1)0.9
Reduced LVEF (≤50%)345 (20)649 (17)11.3208 (17.6)174 (14.7)6.3
Critical preoperative state54 (3.1)94 (2.4)6.530 (2.5)30 (2.5)
Urgent/emergent status124 (7.1)234 (6)5.275 (6.3)75 (6.3)
EuroSCORE II, median (IQR)1.58 (0.9–3.1)1.1 (0.73–2.01)14.91.41 (0.83–2.94)1.29 (0.91–2.13)9.4

AF: atrial fibrillation; CABG: coronary artery bypass grafting; IQR: interquartile range; NYHA: New York Heart Association.

Table 6:

Operative data (N = 5626)

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
Surgical approach<0.001<0.001
 Direct vision795 (45.5)989 (2.5)467 (39.4)342 (28.9)
 Video assisted507 (29)1697 (43.8)347 (29.3)433 (36.5)
 Totally endoscopic401 (22.9)1177 (30.4)332 (28)410 (34.6)
 Robotic46 (2.6)8 (0.2)38 (3.2)1 (0.1)
Surgical access<0.001<0.001
 Antrolateral806 (46.1)2939 (75.8)615 (51.9)788 (66.5)
 Transaxillary570 (32.6)348 (9)298 (25.2)152 (12.8)
 Periareolar80 (4.6)583 (15)62 (5.2)244 (20.6)
 Ministernotomy293 (16.8)5 (0.1)210 (17.7)1 (0.1)
Conversion to full sternotomy39 (2.2)56 (1.4)0.0431 (2.6)19 (1.6)0.1
Arterial cannulation site<0.001<0.001
 Femoral artery1317 (80.2)3791 (97.9)955 (80.6)1169 (98.6)
 Axillary artery15 (0.9)39 (1)11 (0.9)10 (0.8)
 Ascending aorta296 (18)17 (0.4)212 (17.9)4 (0.3)
 Other14 (0.9)27 (0.7)7 (0.6)2 (0.2)
Myocardial protection<0.001<0.001
 Cardioplegia1719 (98.2)3798 (98)1170 (98.7)1158 (97.7)
 Ventricular fibrillation13 (0.7)69 (1.8)5 (0.4)25 (2.1)
 Beating heart18 (1)7 (0.2)10 (0.8)2 (0.2)
Aortic cross-clamping type<0.0010.006
 External clamp1658 (96.2)3524 (92)1121 (95.6)1086 (93)
 Endoclamp65 (3.8)306 (8)51 (4.4)82 (7)
Type of surgery<0.001<0.001
Mitral valve repair1202 (68.7)3213 (82.9)893 (75.4)976 (82.4)
Mitral valve replacement548 (31.3)662 (17.1)292 (24.6)209 (17.6)
Concomitant tricuspid surgery361 (20.6)654 (16.9)<0.001230 (19.4)186 (15.7)0.02
Concomitant AF surgery250 (14.3)757 (19.5)<0.001184 (15.5)159 (13.4)0.2
LAA closure270 (15.4)592 (15.3)0.8191 (16.1)157 (13.2)0.03
Repeated cross-clamping40 (2.3)104 (2.7)0.425 (2.1)32 (2.7)0.4
CPB time, median (IQR)140 (114–176)134 (103–178)<0.001142 (113–176)133 (106–176)<0.001
Cross-clamp time, median (IQR)83 (64–109)80 (59–107)0.00485 (65–111)82 (61–106)0.005
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
Surgical approach<0.001<0.001
 Direct vision795 (45.5)989 (2.5)467 (39.4)342 (28.9)
 Video assisted507 (29)1697 (43.8)347 (29.3)433 (36.5)
 Totally endoscopic401 (22.9)1177 (30.4)332 (28)410 (34.6)
 Robotic46 (2.6)8 (0.2)38 (3.2)1 (0.1)
Surgical access<0.001<0.001
 Antrolateral806 (46.1)2939 (75.8)615 (51.9)788 (66.5)
 Transaxillary570 (32.6)348 (9)298 (25.2)152 (12.8)
 Periareolar80 (4.6)583 (15)62 (5.2)244 (20.6)
 Ministernotomy293 (16.8)5 (0.1)210 (17.7)1 (0.1)
Conversion to full sternotomy39 (2.2)56 (1.4)0.0431 (2.6)19 (1.6)0.1
Arterial cannulation site<0.001<0.001
 Femoral artery1317 (80.2)3791 (97.9)955 (80.6)1169 (98.6)
 Axillary artery15 (0.9)39 (1)11 (0.9)10 (0.8)
 Ascending aorta296 (18)17 (0.4)212 (17.9)4 (0.3)
 Other14 (0.9)27 (0.7)7 (0.6)2 (0.2)
Myocardial protection<0.001<0.001
 Cardioplegia1719 (98.2)3798 (98)1170 (98.7)1158 (97.7)
 Ventricular fibrillation13 (0.7)69 (1.8)5 (0.4)25 (2.1)
 Beating heart18 (1)7 (0.2)10 (0.8)2 (0.2)
Aortic cross-clamping type<0.0010.006
 External clamp1658 (96.2)3524 (92)1121 (95.6)1086 (93)
 Endoclamp65 (3.8)306 (8)51 (4.4)82 (7)
Type of surgery<0.001<0.001
Mitral valve repair1202 (68.7)3213 (82.9)893 (75.4)976 (82.4)
Mitral valve replacement548 (31.3)662 (17.1)292 (24.6)209 (17.6)
Concomitant tricuspid surgery361 (20.6)654 (16.9)<0.001230 (19.4)186 (15.7)0.02
Concomitant AF surgery250 (14.3)757 (19.5)<0.001184 (15.5)159 (13.4)0.2
LAA closure270 (15.4)592 (15.3)0.8191 (16.1)157 (13.2)0.03
Repeated cross-clamping40 (2.3)104 (2.7)0.425 (2.1)32 (2.7)0.4
CPB time, median (IQR)140 (114–176)134 (103–178)<0.001142 (113–176)133 (106–176)<0.001
Cross-clamp time, median (IQR)83 (64–109)80 (59–107)0.00485 (65–111)82 (61–106)0.005

AF: atrial fibrillation; CPB: cardiopulmonary bypass; IQR: interquartile range; LAA: left atrial appendage.

Table 6:

Operative data (N = 5626)

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
Surgical approach<0.001<0.001
 Direct vision795 (45.5)989 (2.5)467 (39.4)342 (28.9)
 Video assisted507 (29)1697 (43.8)347 (29.3)433 (36.5)
 Totally endoscopic401 (22.9)1177 (30.4)332 (28)410 (34.6)
 Robotic46 (2.6)8 (0.2)38 (3.2)1 (0.1)
Surgical access<0.001<0.001
 Antrolateral806 (46.1)2939 (75.8)615 (51.9)788 (66.5)
 Transaxillary570 (32.6)348 (9)298 (25.2)152 (12.8)
 Periareolar80 (4.6)583 (15)62 (5.2)244 (20.6)
 Ministernotomy293 (16.8)5 (0.1)210 (17.7)1 (0.1)
Conversion to full sternotomy39 (2.2)56 (1.4)0.0431 (2.6)19 (1.6)0.1
Arterial cannulation site<0.001<0.001
 Femoral artery1317 (80.2)3791 (97.9)955 (80.6)1169 (98.6)
 Axillary artery15 (0.9)39 (1)11 (0.9)10 (0.8)
 Ascending aorta296 (18)17 (0.4)212 (17.9)4 (0.3)
 Other14 (0.9)27 (0.7)7 (0.6)2 (0.2)
Myocardial protection<0.001<0.001
 Cardioplegia1719 (98.2)3798 (98)1170 (98.7)1158 (97.7)
 Ventricular fibrillation13 (0.7)69 (1.8)5 (0.4)25 (2.1)
 Beating heart18 (1)7 (0.2)10 (0.8)2 (0.2)
Aortic cross-clamping type<0.0010.006
 External clamp1658 (96.2)3524 (92)1121 (95.6)1086 (93)
 Endoclamp65 (3.8)306 (8)51 (4.4)82 (7)
Type of surgery<0.001<0.001
Mitral valve repair1202 (68.7)3213 (82.9)893 (75.4)976 (82.4)
Mitral valve replacement548 (31.3)662 (17.1)292 (24.6)209 (17.6)
Concomitant tricuspid surgery361 (20.6)654 (16.9)<0.001230 (19.4)186 (15.7)0.02
Concomitant AF surgery250 (14.3)757 (19.5)<0.001184 (15.5)159 (13.4)0.2
LAA closure270 (15.4)592 (15.3)0.8191 (16.1)157 (13.2)0.03
Repeated cross-clamping40 (2.3)104 (2.7)0.425 (2.1)32 (2.7)0.4
CPB time, median (IQR)140 (114–176)134 (103–178)<0.001142 (113–176)133 (106–176)<0.001
Cross-clamp time, median (IQR)83 (64–109)80 (59–107)0.00485 (65–111)82 (61–106)0.005
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
Surgical approach<0.001<0.001
 Direct vision795 (45.5)989 (2.5)467 (39.4)342 (28.9)
 Video assisted507 (29)1697 (43.8)347 (29.3)433 (36.5)
 Totally endoscopic401 (22.9)1177 (30.4)332 (28)410 (34.6)
 Robotic46 (2.6)8 (0.2)38 (3.2)1 (0.1)
Surgical access<0.001<0.001
 Antrolateral806 (46.1)2939 (75.8)615 (51.9)788 (66.5)
 Transaxillary570 (32.6)348 (9)298 (25.2)152 (12.8)
 Periareolar80 (4.6)583 (15)62 (5.2)244 (20.6)
 Ministernotomy293 (16.8)5 (0.1)210 (17.7)1 (0.1)
Conversion to full sternotomy39 (2.2)56 (1.4)0.0431 (2.6)19 (1.6)0.1
Arterial cannulation site<0.001<0.001
 Femoral artery1317 (80.2)3791 (97.9)955 (80.6)1169 (98.6)
 Axillary artery15 (0.9)39 (1)11 (0.9)10 (0.8)
 Ascending aorta296 (18)17 (0.4)212 (17.9)4 (0.3)
 Other14 (0.9)27 (0.7)7 (0.6)2 (0.2)
Myocardial protection<0.001<0.001
 Cardioplegia1719 (98.2)3798 (98)1170 (98.7)1158 (97.7)
 Ventricular fibrillation13 (0.7)69 (1.8)5 (0.4)25 (2.1)
 Beating heart18 (1)7 (0.2)10 (0.8)2 (0.2)
Aortic cross-clamping type<0.0010.006
 External clamp1658 (96.2)3524 (92)1121 (95.6)1086 (93)
 Endoclamp65 (3.8)306 (8)51 (4.4)82 (7)
Type of surgery<0.001<0.001
Mitral valve repair1202 (68.7)3213 (82.9)893 (75.4)976 (82.4)
Mitral valve replacement548 (31.3)662 (17.1)292 (24.6)209 (17.6)
Concomitant tricuspid surgery361 (20.6)654 (16.9)<0.001230 (19.4)186 (15.7)0.02
Concomitant AF surgery250 (14.3)757 (19.5)<0.001184 (15.5)159 (13.4)0.2
LAA closure270 (15.4)592 (15.3)0.8191 (16.1)157 (13.2)0.03
Repeated cross-clamping40 (2.3)104 (2.7)0.425 (2.1)32 (2.7)0.4
CPB time, median (IQR)140 (114–176)134 (103–178)<0.001142 (113–176)133 (106–176)<0.001
Cross-clamp time, median (IQR)83 (64–109)80 (59–107)0.00485 (65–111)82 (61–106)0.005

AF: atrial fibrillation; CPB: cardiopulmonary bypass; IQR: interquartile range; LAA: left atrial appendage.

Table 7:

In-hospital results

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
In-hospital mortality29 (1.7)53 (1.4)0.415 (1.3)18 (1.5)0.7
Stroke26 (1.5)53 (1.4)0.714 (1.2)8 (0.7)0.2
Delirium177 (10.1)218 (5.6)<0.001103 (8.7)60 (5.1)<0.001
Intubation time (h), median (IQR)8 (5–15)7 (5–12)<0.0018 (5–14)7 (5–12)<0.001
Bleeding requiring revision95 (5.5)260 (6.7)0.0263 (5.3)66 (5.6)0.8
New-onset AF270 (15.4)567 (14.6)0.4191 (16.1)189 (15.9)0.9
Definitive PM implantation53 (3)72 (1.9)0.00839 (3.3)24 (2)0.07
Myocardial infarction12 (0.7)33 (0.8)0.59 (0.8)12 (1)0.2
Low cardiac output syndrome126 (7.7)114 (2.9)<0.00179 (6.7)41 (3.5)<0.001
Dialysis35 (1.8)42 (1.1)0.0318 (1.5)13 (1.1)0.5
Vascular complications29 (1.7)78 (2)0.0520 (1.7)27 (2.3)0.1
Major vasc. complications15 (0.9)59 (1.5)9 (0.8)19 (1.6)
Minor vasc. complications14 (0.8)19 (0.5)11 (0.9)8 (0.7)
Thoracic wound complications50 (2.9)41 (1.1)<0.0017 (0.6)17 (1.4)0.06
Redo for early valve repair failure12 (0.7)35 (0.9)0.612 (1)7 (0.6)0.3
ICU stay (h), median (IQR)23 (18–48)24 (19–48)<0.00123 (19.48)24 (19–48)0.2
Hospital stay (days), median (IQR)9 (8–15)8 (6–11)<0.0019 (7–14)7 (6–10)<0.001
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
In-hospital mortality29 (1.7)53 (1.4)0.415 (1.3)18 (1.5)0.7
Stroke26 (1.5)53 (1.4)0.714 (1.2)8 (0.7)0.2
Delirium177 (10.1)218 (5.6)<0.001103 (8.7)60 (5.1)<0.001
Intubation time (h), median (IQR)8 (5–15)7 (5–12)<0.0018 (5–14)7 (5–12)<0.001
Bleeding requiring revision95 (5.5)260 (6.7)0.0263 (5.3)66 (5.6)0.8
New-onset AF270 (15.4)567 (14.6)0.4191 (16.1)189 (15.9)0.9
Definitive PM implantation53 (3)72 (1.9)0.00839 (3.3)24 (2)0.07
Myocardial infarction12 (0.7)33 (0.8)0.59 (0.8)12 (1)0.2
Low cardiac output syndrome126 (7.7)114 (2.9)<0.00179 (6.7)41 (3.5)<0.001
Dialysis35 (1.8)42 (1.1)0.0318 (1.5)13 (1.1)0.5
Vascular complications29 (1.7)78 (2)0.0520 (1.7)27 (2.3)0.1
Major vasc. complications15 (0.9)59 (1.5)9 (0.8)19 (1.6)
Minor vasc. complications14 (0.8)19 (0.5)11 (0.9)8 (0.7)
Thoracic wound complications50 (2.9)41 (1.1)<0.0017 (0.6)17 (1.4)0.06
Redo for early valve repair failure12 (0.7)35 (0.9)0.612 (1)7 (0.6)0.3
ICU stay (h), median (IQR)23 (18–48)24 (19–48)<0.00123 (19.48)24 (19–48)0.2
Hospital stay (days), median (IQR)9 (8–15)8 (6–11)<0.0019 (7–14)7 (6–10)<0.001

AF: atrial fibrillation; IQR: interquartile range.

Table 7:

In-hospital results

CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
In-hospital mortality29 (1.7)53 (1.4)0.415 (1.3)18 (1.5)0.7
Stroke26 (1.5)53 (1.4)0.714 (1.2)8 (0.7)0.2
Delirium177 (10.1)218 (5.6)<0.001103 (8.7)60 (5.1)<0.001
Intubation time (h), median (IQR)8 (5–15)7 (5–12)<0.0018 (5–14)7 (5–12)<0.001
Bleeding requiring revision95 (5.5)260 (6.7)0.0263 (5.3)66 (5.6)0.8
New-onset AF270 (15.4)567 (14.6)0.4191 (16.1)189 (15.9)0.9
Definitive PM implantation53 (3)72 (1.9)0.00839 (3.3)24 (2)0.07
Myocardial infarction12 (0.7)33 (0.8)0.59 (0.8)12 (1)0.2
Low cardiac output syndrome126 (7.7)114 (2.9)<0.00179 (6.7)41 (3.5)<0.001
Dialysis35 (1.8)42 (1.1)0.0318 (1.5)13 (1.1)0.5
Vascular complications29 (1.7)78 (2)0.0520 (1.7)27 (2.3)0.1
Major vasc. complications15 (0.9)59 (1.5)9 (0.8)19 (1.6)
Minor vasc. complications14 (0.8)19 (0.5)11 (0.9)8 (0.7)
Thoracic wound complications50 (2.9)41 (1.1)<0.0017 (0.6)17 (1.4)0.06
Redo for early valve repair failure12 (0.7)35 (0.9)0.612 (1)7 (0.6)0.3
ICU stay (h), median (IQR)23 (18–48)24 (19–48)<0.00123 (19.48)24 (19–48)0.2
Hospital stay (days), median (IQR)9 (8–15)8 (6–11)<0.0019 (7–14)7 (6–10)<0.001
CharacteristicsOverall cohort
Propensity-matched cohort
CT group (n = 1750), N (%)No CT group (n = 3876), N (%)P-valueCT group (n = 1185), N (%)No CT group (n = 1185), N (%)P-value
In-hospital mortality29 (1.7)53 (1.4)0.415 (1.3)18 (1.5)0.7
Stroke26 (1.5)53 (1.4)0.714 (1.2)8 (0.7)0.2
Delirium177 (10.1)218 (5.6)<0.001103 (8.7)60 (5.1)<0.001
Intubation time (h), median (IQR)8 (5–15)7 (5–12)<0.0018 (5–14)7 (5–12)<0.001
Bleeding requiring revision95 (5.5)260 (6.7)0.0263 (5.3)66 (5.6)0.8
New-onset AF270 (15.4)567 (14.6)0.4191 (16.1)189 (15.9)0.9
Definitive PM implantation53 (3)72 (1.9)0.00839 (3.3)24 (2)0.07
Myocardial infarction12 (0.7)33 (0.8)0.59 (0.8)12 (1)0.2
Low cardiac output syndrome126 (7.7)114 (2.9)<0.00179 (6.7)41 (3.5)<0.001
Dialysis35 (1.8)42 (1.1)0.0318 (1.5)13 (1.1)0.5
Vascular complications29 (1.7)78 (2)0.0520 (1.7)27 (2.3)0.1
Major vasc. complications15 (0.9)59 (1.5)9 (0.8)19 (1.6)
Minor vasc. complications14 (0.8)19 (0.5)11 (0.9)8 (0.7)
Thoracic wound complications50 (2.9)41 (1.1)<0.0017 (0.6)17 (1.4)0.06
Redo for early valve repair failure12 (0.7)35 (0.9)0.612 (1)7 (0.6)0.3
ICU stay (h), median (IQR)23 (18–48)24 (19–48)<0.00123 (19.48)24 (19–48)0.2
Hospital stay (days), median (IQR)9 (8–15)8 (6–11)<0.0019 (7–14)7 (6–10)<0.001

AF: atrial fibrillation; IQR: interquartile range.

DISCUSSION

In the present study, we evaluated the neurological outcomes and predictors of stroke after mini-MVS using data from the largest worldwide registry for mini-MVS. Moreover, we assessed the role of preoperative CT scan on surgical management and neurological outcomes.

The main results are as follows: (i) while the incidence of stroke in mini-MVS was very low, when it occurs had an ominus impact on mortality, (ii) advanced age, coronary artery disease, urgent emergent status and mitral valve replacement were significant predictors for stroke and (iii) preoperative CT scan performed in selected higher-risk patients affected surgical strategy and likely led to improved neurological outcomes.

Mini-MVS has been adopted for >30 years, since Carpentier reported the first successful case [15]. During these years, the minimally invasive techniques have greatly evolved and nowadays have become the routine approach in many specialized high-volume centres. However, there is still doubt about associated risk and detractors of the minimally invasive cardiac surgery claim that patients are exposed to a greater neurological risk. In 2010, a consensus statement of the International Society of Minimally Invasive Coronary Surgery stated that in patients with mitral disease, minimally invasive surgery could be an alternative to conventional surgery, but with an increasing risk of stroke [16]. Potential reasons for the increased risk of stroke included: incomplete or ineffective de-airing, retrograde aortic flow during CPB, use of CO2 insufflation, air embolism, prolonged cross-clamp and CPB time and the use of endoaortic balloon. Recently, data from 2 large metanalyses disproved this assumption showing comparable results between mini-MVS and full sternotomy MVS [17, 18]. Our study confirmed that mini-MVS is associated with a very low incidence of neurologic injury. In MMIR, the overall incidence of stroke was 1.3% being only 1.1% in the isolated MVS. These results compare favourably with those reported by other international registries on conventional MVS [19]. These improvements may be explained by the evolution in terms of technology and surgeons’ experience, which allowed to overcome some technical challenges like worse exposure and de-airing.

Although the incidence was very low, the occurrence of stroke remains a devastating complication after cardiac surgery. In MMIR, the mortality rate was 7 times higher in patients with postoperative stroke (11.6% vs 1.5%). On multivariable logistic regression, we have identified 3 preoperative and 1 intraoperative risk factors independently associated with the development of postoperative stroke: advanced age, urgent/emergent status and mitral valve replacement. These results are consistent with those reported in most series where age has been identified as a strong predictor of postoperative stroke due to the underlying conditions [20, 21]. Moreover, our findings get stronger what showed in a recent meta-analysis comparing MV repair over replacement, showing postoperative neurological complications in favour of repair over replacement [22]. Although in the past retrograde perfusion was associated with an increased risk of stroke and postoperative delirium [23], in the present study, the site of cannulation did not affect neurological outcomes.

Another topic of discussion is the need of preoperative CT scan screening in minimally invasive surgery. It is well known that it is very useful to assess preoperatively the chest anatomy and to identify the presence of peripheral vascular disease as well as potential contraindications, such as severely calcified aortopathy. Recent data showed that systematic preoperative CT scan screening seems to be associated with lower risk of postoperative stoke and need for dialysis after mini-MVS [24]. In MMIR, a preoperative CT scan was not routinely performed in all cases and was predominantly made in higher-risk patients. Performing CT scan in such selected patients resulted in similar incidence of mortality (1.7% and 1.4%, P = NS) and stroke (1.5% vs 1.4%, P = NS) between the CT group and the no CT group. However, CT scan influenced the choice of cannulation site, being ascending aorta more frequently cannulated in the CT group and femoral artery more frequently cannulated in the no CT group.

Limitations

Despite the strength of our multicentre international registry study, it is a retrospective observational analysis, with its intrinsic limitations. Moreover, indication and subsequent type of mini-MVS were assessed independently by each local institution that was responsible for the data collection and transmission. This study provides no information about the prevalence of mitral annulus calcification that it is a major risk factor for complications including stroke. The comparison of mortality in patients with and without stroke is merely descriptive and was not adjusted for confounders.

CONCLUSIONS

The present study showed that mini-MVS is associated with a low incidence of perioperative stroke, but when it occurs it has an ominous impact on mortality. Age, urgent/emergent status and mitral valve replacement emerged as independent predictors of stroke. In our experience, preoperative CT scan, performed in selected higher-risk patients, affected surgical cannulation strategy and did not led to improved neurological outcomes.

SUPPLEMENTARY MATERIAL

Supplementary material is available at EJCTS online.

Funding

This work was not supported.

Conflict of interest: Nikolaos Bonaros receives speaker's honoraria from Edwards Lifesciences and Medtronic; institutional grant from Edwards Lifesciences and Corcym; and travel grants from Abbott, Medtronic and Edwards Lifesciences. Jorg Kempfert receives speaker’s honoraria from Edwards, Medtronic, Artivion and Abbott. Marc Gerdisch reports as follows: Edwards Lifescience—consultant, Atrivion—consultant, research support, steering committee, Atricure—consultant, research support, national PI, Zimmer Biomet—consultant, research support, CotMatrix—consultant, research support, national PI and DASI Imaging—advisory board, research. The other authors have nothing to disclose.

DATA AVAILABILITY

All relevant data are available on request to the authors.

Author contributions

Giovanni Domenico Cresce: Investigation; Writing—original draft. Paolo Berretta: Data curation; Formal analysis. Antonio Fiore: Investigation. Manuel Wilbring: Investigation. Marc Gerdisch: Investigation. Antonios Pitsis: Investigation. Mauro Rinaldi: Investigation. Nikolaos Bonaros: Investigation. Jorg Kempfert: Investigation. Tristan Yan: Investigation. Frank Van Praet: Investigation. Hoang Dinh Nguyen: Investigation. Carlo Savini: Investigation. Joseph Lamelas: Investigation. Tom C. Nguyen: Investigation. Pierluigi Stefano: Investigation. Gloria Färber: Investigation. Loris Salvador: Conceptualization. Marco Di Eusanio: Conceptualization; Writing—review & editing.

Reviewer information

European Journal of Cardio-Thoracic Surgery thanks Krishna Khargi, Michel Pompeu Sá and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

REFERENCES

1

Newman
MF
,
Mathew
JP
,
Grocott
HP
,
Mackensen
GB
,
Monk
T
,
Welsh-Bohmer
KA
 et al.  
Central nervous system injury associated with cardiac surgery
.
Lancet
 
2006
;
368
:
694
703
.

2

Selnes
OA
,
Gottesman
RF
,
Grega
MA
,
Baumgartner
WA
,
Zeger
SL
,
McKhann
GM
 et al.  
Cognitive and neurologic outcomes after coronary-artery bypass surgery
.
N Engl J Med
 
2012
;
366
:
250
7
.

3

Raffa
GM
,
Agnello
F
,
Occhipinti
G
,
Miraglia
R
,
Lo Re
V
,
Marrone
G
 et al.  
Neurological complications after cardiac surgery: a retrospective case-control study of risk factors and outcome
.
J Cardiothorac Surg
 
2019
;
14
:
23
.

4

Liu
Y
,
Chen
K
,
Mei
W.
 
Neurological complications after cardiac surgery
.
Curr Opin Anaesthesiol
 
2019
;
32
:
563
7
.

5

Russo
A
,
Grigioni
F
,
Avierinos
J-F
,
Freeman
WK
,
Suri
R
,
Michelena
H
 et al.  
Thromboembolic complications after surgical correction of mitral regurgitation
.
J Am Coll Cardiol
 
2008
;
51
:
1203
11
.

6

Cheng
DC
,
Martin
J
,
Lal
A
,
Diegeler
A
,
Folliguet
TA
,
Nifong
LW
 et al.  
Minimally invasive versus conventional open mitral valve surgery: a meta-analysis and systematic review
.
Innovations (Phila)
 
2011
;
6
:
84
103
.

7

Davierwala
PM
,
Seeburger
J
,
Pfannmueller
B
,
Garbade
J
,
Misfeld
M
,
Borger
MA
 et al.  
Minimally invasive mitral valve surgery: “The Leipzig experience”
.
Ann Cardiothorac Surg
 
2013
;
2
:
744
50
.

8

Grant
SW
,
Hickey
GL
,
Modi
P
,
Hunter
S
,
Akowuah
E
,
Zacharias
J.
 
Propensity-matched analysis of minimally invasive approach versus sternotomy for mitral valve surgery
.
Heart
 
2019
;
105
:
783
9
.

9

Cao
C
,
Gupta
S
,
Chandrakumar
D
,
Nienaber
TA
,
Indraratna
P
,
Ang
SC
et al
A meta-analysis of minimally invasive versus conventional mitral valve repair for patients with degenerative mitral disease
.
Ann Cardiothorac Surg
 
2013
;
2
:
693
703
.

10

MPBO
,
Van den Eynde
J
,
Cavalcanti
LRP
,
Kadyraliev
B
,
Enginoev
S
,
Zhigalov
K
 et al.  
Mitral valve repair with minimally invasive approach vs sternotomy: a meta-analysis of early and late results in randomized and matched observational studies
.
J Card Surg
 
2020
;
35
:
2307
23
.

11

Berretta
P
,
Kempfert
J
,
Van Praet
F
,
Salvador
L
,
Lamelas
J
,
Nguyen
TC
 et al.  
Risk-related clinical outcomes after minimally invasive mitral valve surgery: insights from the mini-mitral international registry (MMIR)
.
Eur J Cardiothorac Surg
 
2023
;
63
:
ezad090
.

12

Vahanian
A
,
Beyersdorf
F
,
Praz
F
,
Milojevic
M
,
Baldus
S
,
Bauersachs
J
 et al. ;
ESC/EACTS Scientific Document Group
.
2021 ESC/EACTS Guidelines for the management of valvular heart disease
.
Eur Heart J
 
2022
;
43
:
561
632
.

13

Nashef
SAM
,
Roques
F
,
Sharples
LD
,
Nilsson
J
,
Smith
C
,
Goldstone
AR
 et al.  
EuroSCORE II
.
Eur J Cardiothorac Surg
 
2012
;
41
:
734
45
.

14

Stone
GW
,
Adams
DH
,
Abraham
WT
,
Kappetein
AP
,
Généreux
P
,
Vranckx
P
 et al. ;
for the Mitral Valve Academic Research Consortium (MVARC)
.
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions
.
J Am Coll Cardiol
 
2015
;
66
:
308
21
.

15

Carpentier
A
,
Loulmet
D
,
Carpentier
A
,
Le Bret
E
,
Haugades
B
,
Dassier
P
 et al.  
Chirurgie à coeur ouvert par vidéo-chirurgie et mini-thoracotomie. Premier cas (valvuloplastie mitrale) opéré avec succès [Open heart operation under videosurgery and minithoracotomy. First case (mitral valvuloplasty) operated with success]
.
C R Acad Sci III
 
1996
;
319
:
219
23
.

16

Falk
V
,
Cheng
DC
,
Martin
J
,
Diegeler
A
,
Folliguet
TA
,
Nifong
LW
 et al.  
Minimally invasive versus open mitral valve surgery: a consensus statement of the international society of minimally invasive coronary surgery (ISMICS) 2010
.
Innovations (Phila)
 
2011
;
6
:
66
76
.

17

Sündermann
SH
,
Sromicki
J
,
Rodriguez Cetina Biefer
H
,
Seifert
B
,
Holubec
T
,
Falk
V
 et al.  
Mitral valve surgery: right lateral minithoracotomy or sternotomy? A systematic review and meta-analysis
.
J Thorac Cardiovasc Surg
 
2014
;
148
:
1989
95.e4
.

18

Al Otaibi
A
,
Gupta
S
,
Belley-Cote
EP
,
Alsagheir
A
,
Spence
J
,
Parry
D
 et al.  
Mini-thoracotomy vs. conventional sternotomy mitral valve surgery: a systematic review and meta-analysis
.
J Cardiovasc Surg (Torino)
 
2017
;
58
:
489
96
.

19

Udesh
R
,
Natarajan
P
,
Jeevanantham
V
,
Gleason
TG
,
Badhwar
V
,
Thirumala
PD.
 
Perioperative strokes following surgical correction of mitral valves: a systematic review and meta-analysis
.
Eur Neurol
 
2017
;
78
:
63
70
.

20

Sultan
I
,
Bianco
V
,
Kilic
A
,
Jovin
T
,
Jadhav
A
,
Jankowitz
B
 et al.  
Predictors and outcomes of ischemic stroke after cardiac surgery
.
Ann Thorac Surg
 
2020
;
110
:
448
56
.

21

Whitlock
R
,
Healey
JS
,
Connolly
SJ
,
Wang
J
,
Danter
MR
,
Tu
JV
 et al.  
Predictors of early and late stroke following cardiac surgery
.
CMAJ
 
2014
;
186
:
905
11
.

22

Di Tommaso
E
,
Rapetto
F
,
Guida
GA
,
Zakkar
M
,
Bruno
VD.
 
Benefits of mitral valve repair over replacement in the elderly: a systematic review and meta-analysis
.
J Card Surg
 
2021
;
36
:
2524
30
.

23

Murzi
M
,
Cerillo
AG
,
Miceli
A
,
Bevilacqua
S
,
Kallushi
E
,
Farneti
P
 et al.  
Antegrade and retrograde arterial perfusion strategy in minimally invasive mitral-valve surgery: a propensity score analysis on 1280 patients
.
Eur J Cardiothorac Surg
 
2013
;
43
:
e167-72
e172
. Jun

24

Leonard
JR
,
Henry
M
,
Rahouma
M
,
Khan
FM
,
Wingo
M
,
Hameed
I
 et al.  
Systematic preoperative CT scan is associated with reduced risk of stroke in minimally invasive mitral valve surgery: a meta-analysis
.
Int J Cardiol
 
2019
;
278
:
300
6
.

ABBREVIATIONS

    ABBREVIATIONS
     
  • CI

    Confidence interval

  •  
  • IQR

    Interquartile range

  •  
  • mini-MVS

    Minimally invasive mitral valve surgery

  •  
  • MMIR

    Mini-Mitral International Registry

  •  
  • MVS

    Mitral valve surgery

  •  
  • OR

    Odds ratio

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)

Supplementary data